share_log

開拓藥業-B：董事會會議日期

KINTOR PHARMA-B: DATE OF BOARD MEETING

香港交易所 ·  Mar 15 04:57
Summary by Moomoo AI
開拓藥業-B（「本公司」）將於2024年3月28日（星期四）召開董事會會議，主要議程為考慮及批准公司及其附屬公司截至2023年12月31日止年度的全年業績及其發佈。該會議由董事會主席、執行董事及行政總裁童友之博士主持，並於2024年3月15日對外公佈。目前，執行董事包括童友之博士、陸群博士及倪翔博士；非執行董事為高維鵬先生、衛舸琪女士及劉澄偉先生；獨立非執行董事則為徐敏博士、楊懷嚴先生及童亮教授。
開拓藥業-B（「本公司」）將於2024年3月28日（星期四）召開董事會會議，主要議程為考慮及批准公司及其附屬公司截至2023年12月31日止年度的全年業績及其發佈。該會議由董事會主席、執行董事及行政總裁童友之博士主持，並於2024年3月15日對外公佈。目前，執行董事包括童友之博士、陸群博士及倪翔博士；非執行董事為高維鵬先生、衛舸琪女士及劉澄偉先生；獨立非執行董事則為徐敏博士、楊懷嚴先生及童亮教授。
OPEN PHARMACEUTICALS - B (THE “COMPANY”) WILL HOLD A BOARD MEETING ON THURSDAY, MARCH 28, 2024. THE MAIN AGENDA IS TO CONSIDER AND APPROVE THE ANNUAL RESULTS OF THE COMPANY AND ITS SUBSIDIARIES FOR THE YEAR ENDED 31 DECEMBER 2023 AND THEIR PUBLICATION. The meeting was hosted by the Chairman of the Board, the Executive Director and the Chief Executive Officer, Dr. Kidfriend, and announced externally on 15 March 2024. Currently, the Executive Directors include Dr. Tou Yui, Dr. Lu Kwan and Dr. Ni Xiang; the Non-Executive Directors are Mr. Gao Wei Peng, Ms. Wei Qi and Mr. Liu Cheng Wei; the Independent Non-Executive Directors are Dr. Xu Min, Mr. Yang Wai-yan and Prof. Tung Liang.
OPEN PHARMACEUTICALS - B (THE “COMPANY”) WILL HOLD A BOARD MEETING ON THURSDAY, MARCH 28, 2024. THE MAIN AGENDA IS TO CONSIDER AND APPROVE THE ANNUAL RESULTS OF THE COMPANY AND ITS SUBSIDIARIES FOR THE YEAR ENDED 31 DECEMBER 2023 AND THEIR PUBLICATION. The meeting was hosted by the Chairman of the Board, the Executive Director and the Chief Executive Officer, Dr. Kidfriend, and announced externally on 15 March 2024. Currently, the Executive Directors include Dr. Tou Yui, Dr. Lu Kwan and Dr. Ni Xiang; the Non-Executive Directors are Mr. Gao Wei Peng, Ms. Wei Qi and Mr. Liu Cheng Wei; the Independent Non-Executive Directors are Dr. Xu Min, Mr. Yang Wai-yan and Prof. Tung Liang.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more